One aspect overshadowed all the others for hearing device manufacturer William Demant in the first six months of the year: The launch of its newest device Oticon Opn, which entered the market in late Q2.
“The main thing giving me joy in the first half of the year is the launch of Oticon Opn and the fantastic reception it has enjoyed in the market. Unfortunately we launched it a bit later than we would have liked, so we had a relatively short sales window in H1. Consequently, the commercial result is perhaps not as some would have hoped. But we have said all along that things will pick up pace in H2, and we still believe that,” says deputy CEO, Søren Nielsen, in an interview with MedWatch.